ARTICLE | Clinical News
BHR-100 progesterone regulatory update
December 14, 2009 8:00 AM UTC
FDA granted Orphan Drug designation for BHR-100 to treat moderate to severe traumatic brain injury (TBI). BHR Pharma LLC, a subsidiary of Besins, plans to begin a Phase III trial of the intravenous pr...